SCHEMBL4485267

SCHEMBL4485267

CN(C)Cc1ccc(N/C(=C2\C(=O)Nc3cc(Cl)ccc32)c2ccc(CC(=O)O)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LSS P48449 2/20 0.43
KDM4E B2RXH2 2/20 0.40
MAPT P10636 1/20 0.40
F10 P00742 3/20 0.40
KLKB1 P03952 1/20 0.40
CPT1A P50416 3/20 0.37
CPT1B Q92523 3/20 0.37
NR1H4 Q96RI1 2/20 0.36
CYP26A1 O43174 2/20 0.36
CYP26B1 Q9NR63 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LRRK2 Q5S007 1/20 0.36
S1PR4 O95977 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4485272 1.00 LSS (0.43) LSSKDM4EMAPTF10KLKB1
SCHEMBL227370 0.92 LSS (0.48) LSSKDM4EMAPTF10KLKB1
SCHEMBL227369 0.92 LSS (0.48) LSSKDM4EMAPTF10KLKB1
SCHEMBL4485552 0.92 F10 (0.44) LSSKDM4EMAPTF10CPT1A
SCHEMBL4485555 0.92 F10 (0.44) LSSKDM4EMAPTF10CPT1A
SCHEMBL226786 0.92 LSS (0.43) LSSKDM4EMAPTF10KLKB1
SCHEMBL226787 0.92 LSS (0.43) LSSKDM4EMAPTF10KLKB1
SCHEMBL4497348 0.91 NR1H4 (0.38) LSSKDM4EMAPTF10KLKB1
SCHEMBL4488877 0.91 ROCK2 (0.41) LSSKDM4EMAPTF10KLKB1
SCHEMBL4497346 0.91 NR1H4 (0.38) LSSKDM4EMAPTF10KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR LSS 2944/4885KDM4E 1648/4885MAPT 545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.